Why the study?
Although pharmacological therapy benefits arterial stiffness and endothelial dysfunction, few overall quantitative evaluations of MRAs exist.
Does mineralocorticoid receptor antagonist therapy improve arterial stiffness and endothelial function compared to control?
Population
Patients across randomized trials evaluating MRA effects
Comparison
MRA treatment vs control
Design
Random-effects meta-analysis of randomized trials
Key result
Mineralocorticoid receptor antagonists significantly reduced pulse wave velocity compared with control (MD -0.75 m/s; 95% CI -1.12 to -0.39; P<0.00001).
Authors
Loading...
Supports MRA use targeting arterial stiffness in hypertension; extends meta-analytic evidence on vascular surrogates beyond BP reduction.
Meta-Analysis (n=515)
Does mineralocorticoid receptor antagonist therapy improve arterial stiffness and endothelial function compared to control?
Effect estimate: MD -0.75 m/s (95% CI -1.12 to -0.39)
p-value: p=<0.00001
MRA therapy significantly improves surrogate markers of arterial stiffness and endothelial function, independent of its blood pressure-lowering effects.
Sakima et al. (2021) conducted a meta-analysis in Arterial stiffness and endothelial dysfunction (n=515). Mineralocorticoid receptor antagonists (MRAs) vs. Control was evaluated on Mean difference of pulse wave velocity (PWV) (MD -0.75 m/s, 95% CI -1.12 to -0.39, p=<0.00001). Mineralocorticoid receptor antagonists significantly reduced pulse wave velocity compared with control (MD -0.75 m/s; 95% CI -1.12 to -0.39; P<0.00001).